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The tumor suppressor Kruppel-like factor 6 (KLF6) is frequently inactivated in hepatocellular carci-
noma (HCC). To unearth downstream transcriptional targets of KLF6, cDNA microarray analysis of
whole liver was compared between KLF6+/+ and KLF6+/ mice. Pituitary tumor transforming gene
1 (PTTG1), an oncogene, was the most up-regulated transcript in KLF6+/ liver. In human HCCs,
KLF6 mRNA was signiﬁcantly decreased, associated with increased PTTG1. In HepG2, KLF6 transcrip-
tionally repressed PTTG1 by direct promoter interaction. Whereas KLF6 downregulation by siRNA
increased HepG2 proliferation, siRNA to PTTG1 was anti-proliferative. PTTG1 downregulation repre-
sents a novel tumor suppressor pathway of KLF6.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Kruppel-like factor 6 (KLF6) is a ubiquitously expressed zinc ﬁn-
ger transcription factor and tumor suppressor gene inactivated in
several human cancers [1,2]. To unearth potential KLF6 targets,
cDNA microarray was performed comparing the transcriptional
proﬁle of liver from KLF6 (+/) mice to livers from KLF6 (+/+) mice.
The microarray analysis uncovered pituitary tumor transforming
gene 1 (PTTG1) as the most highly upregulated gene in KLF6+/
livers compared with control. PTTG1, also known as securin, is a po-
tent oncogene and mitotic checkpoint protein that inhibits sister
chromatid separation [3,4].
The potential importance of both KLF6 and PTTG1 in tumorige-
nicity is reinforced by evidence that both play a role in hepatocel-
lular carcinoma (HCC), through over-expression of PTTG and
reduced expression of KLF6 [5,6]. The PTTG1 promoter contains
GC-rich regions, which represent potential KLF6 binding sites. In
the present study, we explored the potential relationship between
these two molecules. Our results demonstrate direct regulation ofchemical Societies. Published by E
Diseases, Mount Sinai School
170C, New York, NY 10029,
iedman).PTTG1 by KLF6, and provide an additional mechanism whereby
KLF6 displays tumor suppressor activity.
2. Materials and methods
2.1. Array analysis
Complementary DNA microarray analysis of gene expression
was performed as described previously [7]. The Oncomine data-
base (http://www.oncomine.org/) was also used to assess KLF6
expression in the prostate cancer microarray data set [7]. Primary
analysis was done with the Genepix pro 4.0 software package
(Molecular Devices). Cy3/Cy5 ratios were determined for KLF6,
along with various other quality control parameters (e.g., intensity
over local background). The normalized median of ratio values of
the KLF6 and PTTG gene was log2 transformed, ﬁltered for pres-
ence across arrays, and selected for expression levels and patterns
depending on the experimental set.
2.2. Human HCC tissue samples
HCC samples from 16 patients and matched surrounding tissue
(ST), were obtained, all with the approval of the Institutional Re-
view Board (IRB) of all institutions involved, as described previ-
ously [8].lsevier B.V. All rights reserved.
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HCC RNA was extracted using Trizol reagent™ followed by col-
umn puriﬁcation (Qiagen). RNA was assessed for quality by agarose
electrophoresis and accepted for analysis only if the 28S/18S ratio
was >0.7.
Cell line and mouse liver RNA was extracted using RNeasy™
mini kit (Qiagen) and treated with DNAse (Qiagen). A total of
1 lg of RNA was reverse transcribed per reaction using ﬁrst strand
complementary DNA synthesis with random primers (Promega).2.4. Quantitative real-time PCR (qRT-PCR)
Samples were analyzed with SYBR green-based qRT-PCR and
performed on an ABI PRISM 7900HT Sequence Detection System.
The following primers were used: hKLF6 forward 50-CGG ACG
CAC ACA GGA GAA AA-30 and hKLF6 reverse 50-CGG TGT GCT TTC
GGA AGT G-30; mKLF6 forward 50-GAG TTC CTC CGT CAT TTC CA-
30 and mKLF6 reverse 50-GTC GCC ATT ACC CTT GTC AC-30; hPTTG1
forward 50-GGC TTT GGG AAC TGT CAA CAG GAG-30 and hPTTG1
reverse 50-GGC ATC ATC TGA GGC AGG AAC AG-30; mPTTG1 for-
ward 50-CTG GGC ACT GGT GTC AAG-30 and mPTTG1 reverse 50-
GCTGTTTTGGTTGGAGGGG-30; h/mGAPDH forward 50-CAA TGA
CCC CTT CAT TGA CC-30 and h/mGAPDH reverse 50-GAT CTC GCT
CCT GGA AGA TG-30. All experiments were done in triplicate and
independently validated three times. All values were normalized
to GAPDH levels.2.5. Cell culture
HepG2 cells were obtained from American Tissue Culture
Collection (ATCC, Manassas, VA) and were cultured as described
[6].2.6. Transfection assays
Transient transfection was performed with Fugene reagent
according to the manufacturers’ protocol (Roche, Indianapolis,
IN). Vectors for PCIneo-KLF6 overexpression or pSuper-KLF6
knockdown were used as previously described [9,10]. For lucifer-
ase assay, HepG2 cells cultured in 12-well plates (Corning Glass)
were transfected with 1 lg of pCIneo empty vector or pCIneo-
KLF6, with the different PTTG1 promoter constructs as previously
described [11]. Twenty four hours after transfection, luciferase
activity was assayed in 10 ll of lysate using the dual-luciferase re-
porter assay system and a Dynex luminometer. Transfection efﬁ-
ciency was normalized to Renilla luciferase activity.Fig. 1. KLF6 and PTTG1 mRNA levels in KLF6+/mouse livers. Livers were harvested from
KLF6 primers resulted in an average 34% decrease in KLF6 transcript in the KLF6+/ m
compared to wildtype control animals.2.7. Western blot
Cell extracts and mouse liver tissue for Western blotting were
harvested in 1 lysis buffer according to standard protocols using
60 lg protein per lane. Western blotting was performed using a
rabbit polyclonal antibody to KLF6, GAPDH (SC-7158, SC-25778,
respectively; Santa Cruz Biotechnology Inc.), and PTTG1 (34-
1500; Zymed Inc.).
2.8. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed using a
commercial kit according to the manufacturer’s instructions (Ac-
tive Motif – ChIP-IT™ Express). Proteins cross-linked to DNA were
immunoprecipitated with 10 lg of anti-KLF6 antibody (R-173)
(Santa Cruz Biotechnology), anti-histone H3 rabbit antiserum
(07-690) (Upstate Biotechnology, Inc.), or control IgG (sc-2027)
(Santa Cruz Biotechnology) and protein-G-magnetic beads. Geno-
mic sequence primers encompassing the promoter region 246
to 401 upstream of transcriptional start site were used to amplify
immunoprecipitated DNA: forward, 50-CGG CTG TTA AGA CCT GCG
TGA GTG-30; reverse, 50-AAC GGG CTC GGA GCC ATC TAA G-30.
2.9. Analysis of proliferation
Proliferation was determined by assaying [3H]thymidine incor-
poration as previously described [2].
3. Results
3.1. PTTG1 mRNA expression is increased in KLF6 (+/) mouse livers
Livers from either KLF6+/+ or KLF6+/ mice previously gener-
ated by homologous recombination [12] were harvested and cDNA
microarray analysis was performed to screen for genes differen-
tially regulated with loss of a KLF6 allele. Among transcripts that
were upregulated, the most signiﬁcantly increased was PTTG1.
To validate these results, we performed qRT-PCR on 24 additional
KLF6+/+ and +/mouse livers. Along with the expected 50% reduc-
tion of KLF6 mRNA (Fig. 1A) PTTG mRNA was increased 82% in
KLF6+/ livers (Fig. 1B).
3.2. PTTG1 mRNA is over-expressed while KLF6 mRNA is decreased in
HCCs compared to surrounding liver
PTTG1 and KLF6 mRNA expression was analyzed by qRT-PCR in
HCC patient samples and compared to surrounding non-malignant
liver tissue. Of the 16 samples analyzed, there was an average 70%nine WT and nine Het mice and analyzed by qRT-PCR. (A) qRT-PCR with wildtype
ice. (B) The same samples had an average 82% increase in PTTG1 transcript when
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ing tissue. This decrease is consistent with our previous report [8].
Importantly, in these same samples PTTG1 was increased an aver-
age of 200% (Fig. 2). Of the 16 samples, in 75% PTTG1 mRNA was
increased, while the remaining 25% showed no change.
3.3. Reciprocal expression of KLF6 and PTTG1 in HepG2 cells
KLF6 transcriptionally regulates gene expression through bind-
ing to GC-boxes in responsive promoters. We explored KLF6 regu-
lation of PTTG1 by transiently over-expressing KLF6 cDNA or siRNAFig. 2. KLF6 and PTTG1 mRNA levels in HCC patient samples compared with
surrounding tissue. Liver samples were analyzed from 18 patients with HCC by qRT-
PCR. On average, there was a signiﬁcant decrease of 70% (P < 0.0001) in levels of
KLF6 transcript while PTTG1 levels were signiﬁcantly up twofold (P < 0.001).
Fig. 3. PTTG1 is downregulated with KLF6 overexpression. HepG2 cells were transfected
12-fold over-expression of KLF6 with a 24% decease of PTTG1 (P < 0.0005). (B) Sixty mic
submitted to Western blot analysis for KLF6 and PTTG1. GAPDH served as the protein loa
fold overexpression in KLF6. The data presented in (B) is representative of at least three
Fig. 4. PTTG1 is upregulated with KLF6 knockdown. HepG2 cells were transfected with
showed 57% decrease in KLF6 mRNA, with a corresponding 3.7-fold increase in PTTG1. (B
decrease in KLF6 protein levels resulted in approximately twofold overexpression of
experiments.in the HepG2cell line. A 12-fold over-expression of KLF6-pBabe in
HepG2 resulted in 24% decease of PTTG1mRNA assessed by qRT-
PCR (Fig. 3A) and approximately 50% decrease in PTTG1 protein le-
vel (Fig. 3B). Conversely, knockdown of KLF6 with siRNA resulted
in a 57% decrease in KLF6 mRNA, with a corresponding 3.7-fold in-
crease in PTTG1 (Fig. 4A), paralleling changes in expression of PTTG
protein by Western (Fig. 4B). Together these results indicate that
KLF6 regulates expression of PTTG1.
3.4. KLF6 transcriptionally represses PTTG1 promoter activity through
direct promoter interaction
Several GC-boxes in the PTTG1 promoter have been previously
characterized in response to Sp1 and NF-Y transactivation, but also
represent putative binding sites for KLF6. To explore this possibil-
ity, PTTG1 promoter mutation constructs (obtained as a gift from
Dr. Xun Zhang) (Fig. 5A) were transfected into HepG2 cells, with
or without KLF6 cDNA co-transfection. Over-expression of KLF6 re-
pressed the ‘p710’ PTTG1 promoter construct activity by 45%, while
mutation of GC-box-mt2 abrogated this repression (Fig. 5B). These
results suggested that KLF6 directly trans-represses the promoter
of PTTG1. To conﬁrm direct binding of KLF6 to the endogenous
PTTG1promoter, ChIP was performed using nuclear extracts from
HepG2 cells. Binding of KLF6 was evident in the region 246 to
401 nt, which included a GC-box (Fig. 6). Taken together, the data
indicate that KLF6 can functionally repress the PTTG1 gene through
direct binding to the PTTG1 promoter.with KLF6 and RNA and protein collected after 24 h. (A) qRT-PCR on cDNA showed a
rograms of protein from total cell extracts were loaded on 10% SDS–PAGE gel and
ding control. There was approximately a 50% decrease in PTTG1 protein with several
independent experiments.
siKLF6 or siControl and RNA and protein collected after 24 h. (A) qRT-PCR on cDNA
) Protein extracts were submitted to Western blot analysis and approximately a 50%
PTTG1. The data presented in (B) is representative of at least three independent
Fig. 5. PTTG1 promoter activity is decreased with KLF6 over-expression. HepG2 cells were transiently transfected with either pGL3 (promoter-less vector), p710 (minimal
promoter), GC-mt1, GC-mt2, GC-mt3, GC-mt4 (each representing a mutation of a GC-box in the promoter), a combination of GC-mt2 and GC-mt3, or all GC-boxes mutated.
Cells were also transfected with either KLF6 or PCIneo control to assess the ability of KLF6 to repress the PTTG1 promoter. (A) Schematic of PTTG1 promoter representing the
GC-boxes mutated in these experiments. (B) KLF6 represses the p710 PTTG1 promoter by 30%, which was abrogated with mutation of GC-mt2.
Fig. 6. Direct interaction of KLF6 with PTTG promoter by ChIP. HepG2 cells were
cross-linked with formaldehyde, chromatin sheared, and immunoprecipitated with
KLF6 antibody, non-speciﬁc IgG, or positive control H3 antibody. The primers used
span the region 401 to 246 of the PTTG1 promoter. ChIP analysis shown
conﬁrms KLF6 binding to the PTTG1 promoter.
Fig. 7. Silencing of PTTG1 abrogates siKLF6 induced cell proliferation. HepG2 cells
were transfected with either siKLF6, siPTTG1, siControl, or a combination for 24, 48,
and 72 h. Cells were incubated with 1 lCi/ml [3H]thymidine for 2 h before
collection, and analyzed for radioactive thymidine incorporation. The 24 h time
point is set to baseline. siPTTG1 shows a decrease in proliferation compared with
siControl at both 48 and 72 h (P < 0.05), whereas siKLF6 increases proliferation at
both time points. Co-transfection of siPTTG1 and siKLF6 abrogates the increase
mediated by siKLF6 alone.
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proliferation induced by KLF6 loss
In order to establish the biological consequences of PTTG1
repression by KLF6, proliferation assays were performed in HepG2
cells following KLF6 knockdown by siRNA. Decreased levels of full-
length KLF6 promote cell proliferation, which has been ascribed in
part to down-regulation of the cdk/cyclin inhibitor p21 [2], but
upregulation of PTTG1 could represent an additional mechanism
whereby KLF6 loss enhances cell growth. In order to test this
hypothesis, we expressed siRNA to either KLF6, PTTG1, both KLF6
and PTTG1, or control siRNA in HepG2. DNA synthesis in cells
expressing siKLF6 was increased relative to vector-expressing cells,
whereas cells expressing siPTTG1 grew more slowly. However,
when siPTTG1 was co-expressed with siKLF6, DNA synthesis was
restored to baseline levels (Fig. 7).
4. Discussion
HCC is the ﬁfth most frequent neoplasm worldwide with great-
er than 500 000 deaths annually, and is the fasting rising malig-
nancy in the US and Europe [13]. Inactivation of several tumor
suppressor genes including p53, Rb, and p16 has been documented
in a proportion of HCCs [14]. More recently, reduced KLF6 expres-
sion has been observed in both HBV- and HCV-related HCCs [8].
Many cancers over-express PTTG including colon [15] and liver
[4,5,16], among others. PTTG has been associated with tumor inva-
siveness and genetic instability [17], and can transform NIH-3T3
ﬁbroblasts in a dose dependent manner leading to morphological
changes, anchorage-independent growth in soft agar, and en-
hanced tumor formation in nude mice [18,19]. Recently, PTTG dys-
regulation has also been uncovered in HCC, with its increased
expression associated with poor prognosis and increased intratu-
moral microvessel density [4].
Downregulation of PTTG1 by siRNA inhibits cell growth in vitro
and in vivo in sarcomatoid HCC and hepatoma cell lines [5]. This
tumor suppressive phenotype following PTTG1 knockdown may
be partially mediated through increased p53 and apoptotic cell
death [20]. Similarly, siRNA targeting of PTTG in lung tumors re-
duces tumor formation and decreases levels of Ki67, bFGF and
CD34, which may also be relevant to the HCC phenotype [21]. In
this study we show that loss of KLF6-mediated repression of PTTG1
may be an additional genetic defect in HCC. KLF6 loss is an early
1010 U.E. Lee et al. / FEBS Letters 584 (2010) 1006–1010event in the progression of HCC, followed at later stages by a var-
iable frequency of inactivating mutations. The loss of KLF6 and
subsequent upregulation of PTTG1 could contribute to tumorigen-
esis through increased proliferation, angiogenesis, and possibly
chromosomal instability, leading to a wide variety of mutations.
Future studies focusing on the role of KLF6 in chromosomal insta-
bility mediated by PTTG1 yield further insights into this important
pathway in tumorigenesis.
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